Moreover, in multiple myeloma, SETD8 was associated with melphalan resistance and its expression was found to be significantly higher in relapsed patients than in newly diagnosed patients (Herviou et al., 2021). The gene discussed is KMT5A; the disease is plasma cell myeloma.